Executive Editor, MTI; Medtech Editor, In Vivo
Ashley has reported on health care market issues with Citeline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).
Latest From Ashley Yeo
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.
UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment
Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.
The E in ESG: Thermo Fisher On Why The ‘How’ Is More Important Than The ‘When’
Life sciences and diagnostics group Thermo Fisher Scientific is encouraging suppliers to meet the same ambitious climate change targets that it has set for itself – mindful that Scope 3 emissions account for the vast majority of industry’s environmental footprint. But the drive for compliance must not compromise achievements made in the “S in ESG,” says corporate VP, CSR and sustainability, Meron Mathias.
UK Diagnostics Companies Count On Medtech Strategy To Deliver
The UK government’s first ever medtech strategy has received plaudits for its ambition. The diagnostics industry, while supportive of the intent, is waiting for more than just promises.
At The Forefront Of Regulatory Change – BIVDA’s Ashleigh Batchen
In Vivo Rising Leader Ashleigh Batchen has packed a lot of experience of medical device diagnostic regulatory issues into a few short years at the British In Vitro Diagnostics Association and before that the UK MHRA. Her advocacy offers vital support to the IVD industry at the busiest time in UK – and EU – regulatory history.